Director, Wellcome Sanger Institute, UK
Mike Stratton is the Director of the Wellcome Sanger Institute and Chief Executive Officer of the Wellcome Genome Campus.
His primary research interests have been in the genetics of cancer. His early research focused on inherited susceptibility. M. Stratton mapped and identified the major high-risk breast cancer susceptibility gene BRCA2 and subsequently a series of moderate-risk breast cancer and other cancer susceptibility genes.
In 2000 M. Stratton initiated the Cancer Genome Project at the Wellcome Sanger Institute which conducts systematic genome-wide searches for somatic mutations in human cancer. Through these studies he discovered somatic mutations of the BRAF gene in malignant melanoma and several other mutated cancer genes in lung, renal, breast and other cancers. He has described the basic patterns of somatic mutation in cancer genomes revealing underlying DNA mutational and repair processes.
M. Stratton is a Fellow of the Royal Society (FRS) and was Knighted by the Queen in 2013.
